Imiglucerase biosimilar - Bio Sidus S.A.
Latest Information Update: 16 Aug 2013
$50 / €47 *
At a glance
- Originator Bio Sidus S.A.
- Developer Biosidus S.A.
- Class Glucosidases
- Mechanism of Action Glucosylceramidase replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Gaucher's disease
Most Recent Events
- 15 Aug 2013 Investigation in Gaucher's disease in Argentina (IV)